Navigation Links
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
Date:5/21/2009

ewscom.com/cgi-bin/prnh/20031219/LLYLOGO' target='_new'>http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO )

1) Thygesen K, Alpert JA, White HD, et al. Universal Definition of Myocardial Infarction. Circulation 2007;116:2634-2653.

2) Effect of the Novel Thienopyridine Prasugrel Compared with Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the TRITON-TIMI 38 Trial: an Application of the Universal Definition of Myocardial Infaction. Cardiology. Circulation. June 2, 2009.

3) Thygesen K, Alpert JA, White HD, et al. Universal Definition of Myocardial Infarction. Circulation 2007;116;2634-2653.

4) Wiviott, S, Braunwald, E, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine. November 2007;357:2001-15.

5) Ibid

6) American Heart Association. Heart Disease and Stroke Statistics - 2008 Update. Dallas, TX. American Heart Association. (Pg. 14).

7) British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics 2008, http://www.ehnheart.org/content/ItemPublication.asp?docid=7069&level0=1500&level1=2157, Accessed April 24 2008.

8) WebMD Medical Reference in Collaboration with the Cleveland Clinic. Heart Disease: Coronary Artery Disease. June 2004.


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
2. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
3. Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
6. Intrinsic Bioprobes, Inc. Enters into a $1.27M Contract with the National Cancer Institute to Develop Multiplex Mass Spectrometric Immunoassays for Detection of Low Abundance Cancer-Related Proteins
7. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
8. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
9. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
10. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
11. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... Czech Republic (PRWEB) May 25, 2013 ... nanoscale optical manipulation have been recognized with presentation of ... (ICO). The presentations were made 16 April during the ... SPIE, the international society for optics and photonics , ... Jan Perina of Palacký University was presented with the ...
(Date:5/25/2013)... Dennis R. HIll M.D. Radiation Oncologist at the Alta Bates ... has been a promotion of the idea that a newer ... low dose rate, brachytherapy for prostate cancer. The claim is ... half life, and gives a higher biologically effective dose to ... higher average energy than the other commonly used prostate cancer permanent ...
(Date:5/24/2013)... 24, 2013 Dr. Ingrid Warmuth and Anamaria ... NJ, are proud to announce an Open House at their ... on Saturday, June 8th from 10 AM to 2 PM. ... MHS, PA-C and staff will be on hand to talk ... aesthetic treatments, and provide complimentary cosmetic consultations. There will also ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 In ... and industry suppliers will present technologies with applications ... the annual SPIE Optics and Photonics ... by SPIE, the international society for optics ... international, multidisciplinary optical sciences and technology meeting in ...
Breaking Biology Technology:ICO Honors Three with Awards during SPIE Optics and Optoelectronics 2ICO Honors Three with Awards during SPIE Optics and Optoelectronics 3Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 2Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4
... Same Prior Year Period, DUBLIN, Calif., April 28 ... results for the first quarter ended,March 31, 2008., ... million, compared,with $4.4 million for the same prior year ... $8.1 million in royalty revenue, compared,with $3.8 million for ...
... Year, Based on Positive Operating Results and One-Time ... of $122.6 Million, Product Sales Rise 16% to All-Time High of $101.5 Million ... Revenues of ... $455 Million -, SAN DIEGO, April 28 Gen-Probe Incorporated,(Nasdaq: GPRO ) ...
... 28 Simcere,Pharmaceutical Group (NYSE: SCR ), ... and manufacturer of the patented,anti-cancer biotech product Endu ... 3rd Annual Healthcare Trip, to be held May,6-10 ... Weihai., Simcere senior management will give a ...
Cached Biology Technology:SuperGen Reports 2008 First Quarter Financial Results 2SuperGen Reports 2008 First Quarter Financial Results 3SuperGen Reports 2008 First Quarter Financial Results 4SuperGen Reports 2008 First Quarter Financial Results 5SuperGen Reports 2008 First Quarter Financial Results 6SuperGen Reports 2008 First Quarter Financial Results 7SuperGen Reports 2008 First Quarter Financial Results 8SuperGen Reports 2008 First Quarter Financial Results 9Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 2Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 3Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 4Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 5Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 6Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 7Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 8Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 9Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 10Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 11Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 12Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 13Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip 2
(Date:5/22/2013)... a novel technique that can detect molecular variants in ... one of the most important, though time-consuming, processes in ... in Nature , post-doctoral researcher David Patterson, Professor ... the Center for Free-Electron Laser Science (CFEL) in Hamburg, ... fields to identify molecular variants apart, and to determine ...
(Date:5/22/2013)... human health effects from disposal of millions of ... to recommend stronger government policies to encourage recovery, ... That,s the conclusion of a new paper in ... . , Oladele A. Ogunseitan and colleagues point ... powering everything from smart phones to components in ...
(Date:5/22/2013)... 2013 Early screening for prostate cancer could become ... for women, thanks to UC Irvine research published today ... . , After more than a decade of work, ... identify clinically usable markers for prostate cancer in urine, ... with greater accuracy and at dramatically lower cost. The ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
... Safes, a new,report by market research publisher SBI, forecasts that ... 2008 and beyond, topping $308,million by 2011. At $221 million ... safes market. In terms of units, personal safes account,for an ... year in,the U.S., 60% of which are sold in the ...
... Harbor, NY Cancer patients usually ask what can be ... to other organs. In many cases, they learn, little can ... at Cold Spring Harbor Laboratory (CSHL) of a type of ... into large, aggressive metastases the kind that kill cancer ...
... accepted belief that substantial ice sheets could not have ... study by researchers at Scripps Institution of Oceanography at ... ice cap, about half the size of the modern ... during a period of intense global warming. This study ...
Cached Biology News:Personal Safes Market to Top $308 Million by 2011 2CSHL scientists identify cells that promote formation of lethal lung metastases 2A warming climate can support glacial ice 2A warming climate can support glacial ice 3
...
Anti-Human Factor XIII HRPO (Polyclonal) (sheep IgG)...
Recognizes the 41 and 43 kDa G-proteins present in liver plasma membranes and Gq/11alpha expressed in the Sf9 insect cell expression system. Negative for recombinant G(I)alpha subtypes....
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....
Biology Products: